v3.25.4
Equity - Adjusted income from continuing operations attributable to shareholders (Detail) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Equity [Line Items]      
Net income € 897 € (698) € (463)
Discontinued operations, net of income taxes 4 (142) 10
Income from continuing operations 901 (840) (454)
Income from continuing operations attributable to non-controlling interests (1) (3) (2)
Income from continuing operations attributable to shareholders 899 (843) (456)
Amortization and impairment of acquired intangible assets 240 392 290
Impairment of goodwill 0 0 8
Restructuring and acquisition-related charges 260 326 381
Other items: 270 830 1,358
Net finance income/expenses 28 23 18
Tax impact on adjusting items (192) (370) (450)
Tax effect of derecognition of US deferred tax asset 0 941 0
Adjusted Income from continuing operations attributable to shareholders 1,506 1,300 1,148
Respironics litigation provision      
Equity [Line Items]      
Other items: 0 984 575
Respironics insurance income      
Equity [Line Items]      
Other items: 0 (538) 0
Respironics field-action connected to the proposed consent decree      
Equity [Line Items]      
Other items: 97 113 363
Respironics field-action running costs      
Equity [Line Items]      
Other items: 112 133 224
Contract settlement gain      
Equity [Line Items]      
Other items: (27) 0 0
Quality actions      
Equity [Line Items]      
Other items: 89 123 175
Provision for a legal matter      
Equity [Line Items]      
Other items: 0 0 31
Investment re-measurement loss      
Equity [Line Items]      
Other items: 0 0 23
Loss (gain) on divestment of business      
Equity [Line Items]      
Other items: 0 0 (35)
Remaining items      
Equity [Line Items]      
Other items: € (1) € 16 € 2